Cost-Effectiveness of Ultrasound Renal Denervation for Resistant Hypertension in Belgium, France and The Netherlands

Rod S. Taylor (), Kaylie Metcalfe, Antoine Cremer, Sofie Brouwers, Joost Daemen, Sam Carter, Kieran Murphy, Marie-Claude Morice, Isabelle Durand-Zaleski, Linh Ngo, Michel Azizi and Ajay J. Kirtane
Additional contact information
Rod S. Taylor: University of Glasgow
Kaylie Metcalfe: Mtech Access Limited
Antoine Cremer: Saint André Hospital
Sofie Brouwers: Vrije Universiteit Brussels
Joost Daemen: Erasmus University Medical Center
Sam Carter: ReCor Medical
Kieran Murphy: ReCor Medical
Marie-Claude Morice: European Center for Cardiovascular Research (CERC)
Isabelle Durand-Zaleski: Université de Paris, CRESS, INSERM, INRA, URCEco, AP-HP, Hôpital de l’Hôtel Dieu, Paris, Santé Publique Hôpital Henri Mondor
Linh Ngo: European Center for Cardiovascular Research (CERC)
Michel Azizi: Université Paris Cité; NSERM, CIC1418
Ajay J. Kirtane: Columbia University Irving Medical Center/New York Presbyterian Hospital

PharmacoEconomics - Open, 2025, vol. 9, issue 4, No 5, 585-595

Abstract: Abstract Background Endovascular ultrasound renal denervation (uRDN) with the Paradise System has emerged as an adjunctive treatment option for the management of uncontrolled resistant hypertension (rHTN). This study assesses the cost-effectiveness of uRDN for rHTN across three European countries—Belgium, France and the Netherlands. Methods On the basis of a previously developed state-transition Markov model, we projected costs, life years (LYs) and quality adjusted life years (QALYs) with the addition of uRDN to standard of care (SoC) compared with SoC alone over patient lifetime. Analyses were based on the RADIANCE-HTN TRIO trial, which demonstrated a mean reduction in office systolic blood pressure from a baseline of 8.5 mmHg at 2 months post-uRDN among patients with rHTN. Mortality and costs data were separately sourced and applied for each country independently. Country-specific discount rates were applied to both cost and outcomes. One-way and probabilistic sensitivity analyses were conducted to assess the uncertainty surrounding the model inputs and sensitivity of the model results to changes in parameter inputs. Results were reported as incremental cost-effectiveness ratios (ICERs). Results The base-case analyses of the models for all three countries show uRDN plus SoC results in improvement in both LYs and QALYs per patient and higher costs compared with SoC alone. The mean ICERs for each country model fall well below the respective country-specific willingness-to-pay thresholds (WTPs)—Belgium: WTP €40,000 and ICER €4426/QALY gained; France: WTP €50,000 and ICER €6261/QALY gained; and the Netherlands: WTP €20,000 and ICER €1654/QALY gained. Results were robust across scenarios and sensitivity analyses. Conclusions The addition of endovascular uRDN offers clinicians and payers a cost-effective adjunctive treatment approach alongside hypertensive medication for the management of rHTN in the healthcare systems of Belgium, France and the Netherlands.

Date: 2025
References: Add references at CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s41669-025-00574-2 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:pharmo:v:9:y:2025:i:4:d:10.1007_s41669-025-00574-2

Ordering information: This journal article can be ordered from
http://www.springer.com/adis/journal/41669

DOI: 10.1007/s41669-025-00574-2

Access Statistics for this article

PharmacoEconomics - Open is currently edited by Timothy Wrightson and Christopher Carswell

More articles in PharmacoEconomics - Open from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().